Trials / Completed
CompletedNCT03613662
A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102
An Open-label, Single-arm Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects With Lumbosacral Radiculopathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Semnur Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single-arm, repeat dose study to characterize the pharmacodynamics and safety/tolerability of SP-102 administered by epidural injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SP-102 | Injection |
Timeline
- Start date
- 2018-07-13
- Primary completion
- 2019-03-15
- Completion
- 2019-03-15
- First posted
- 2018-08-03
- Last updated
- 2022-01-13
- Results posted
- 2022-01-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03613662. Inclusion in this directory is not an endorsement.